ArticleCell reports. Medicine2023
Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma.
Open access · goldAbstract read
In one paragraph
Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- Pan-tumor harmonization of pathologic response assessment for standardized data collection in neoadjuvant trials (PATHdata): results of a Society for Immunotherapy of Cancer multi-institutional reproducibility study.Annals of oncology : official journal of the European Society for Medical Oncology · 2026Article
- Deciphering the mechanistic landscape of immune checkpoint blockade in ccRCC: from molecular drivers to therapeutic responses.Frontiers in immunology · 2026Review
- Computed tomography-based unsupervised clustering identifies clusters associated with progression free survival in clear cell renal cell carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors.Nature reviews. Nephrology · 2025Review
- High pathological tumor response associates with enhanced overall survival in HNSCC patients following neoadjuvant immunochemotherapy and surgery.World journal of surgical oncology · 2025Article
- Prognostic impact of extracellular volume fraction derived from equilibrium contrast-enhanced CT in HCC patients receiving immune checkpoint inhibitors.Scientific reports · 2025Article
- Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols.Journal for immunotherapy of cancer · 2025Article
- Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions.Frontiers in immunology · 2025Review
- Dynamic Changes in Serum Immunoglobulin G Predict Clinical Response and Prognosis in Metastatic Clear-cell Renal Cell Carcinoma.European urology open science · 2024Article
- Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockade.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Immunotherapy of Clear-Cell Renal-Cell Carcinoma.Cancers · 2024Review
- Established and emerging biomarkers of immunotherapy in renal cell carcinoma.Immunotherapy · 2024Review
- Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non-small cell lung cancer.Journal of pathology and translational medicine · 2024Review
- The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023.The oncologist · 2024Article
- Association between pathologic response and survival after neoadjuvant therapy in lung cancer.Nature medicine · 2024Article
- Genomic Profiling and Molecular Characterization of Clear Cell Renal Cell Carcinoma.Current oncology (Toronto, Ont.) · 2023Review
- Single-Cell RNA-Seq Analysis Reveals Ferroptosis in the Tumor Microenvironment of Clear Cell Renal Cell Carcinoma.International journal of molecular sciences · 2023Article
- Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition.F1000Research · 2023Article
- CXCL14 as a potential marker for immunotherapy response prediction in renal cell carcinoma.Therapeutic advances in medical oncology · 2023Article
- Round up.Indian journal of urology : IJU : journal of the Urological Society of IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 1 country.
Julie Stein DeutschDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA.
Evan J LipsonDepartment of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA; The Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD 21287, USA.
Ludmila DanilovaDepartment of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA; The Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD 21287, USA.
Suzanne L TopalianDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA; The Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD 21287, USA.
Jaroslaw JedrychDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA; Department of Dermatology, Johns Hopkins University, Baltimore, MD 21287, USA.
Ezra BarabanDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA.
Yasser GedDepartment of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA.
Nirmish SinglaDepartment of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA.
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Saurabh GuptaBristol-Myers Squibb, Princeton, NJ, USA.
Robert J MotzerDepartment of Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
David McDermottDepartment of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Sabina SignorettiDepartment of Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
Michael AtkinsGeorgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
Janis M TaubeDepartment of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD 21287, USA; Department of Dermatology, Johns Hopkins University, Baltimore, MD 21287, USA; The Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD 21287, USA. Electronic address: jtaube1@jhmi.edu.
Johns Hopkins University · USBloomberg (United States) · USDana-Farber Cancer Institute · USBeth Israel Deaconess Medical Center · USBristol-Myers Squibb (United States) · USGeorgetown Lombardi Comprehensive Cancer CenterMemorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MVectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI A. Heather Eliassen · 1985 to 2026
$330.6MTranslational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6MTreating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4MPD-1/PD-L1 modulation in cancer therapyR01CA142779 · NCI · JOHNS HOPKINS UNIVERSITY · PI PARDOLL, DREW M., TAUBE, JANIS M · 2010 to 2025
$8.2MOpportunities for Pathology Trainees in Cancer ResearchT32CA193145 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANDERS, ROBERT A., EBERHART, CHARLES G · 2015 to 2025
$2.6MComprehensive Analysis and Multi-Omics Data Integration for Cancer-Related StudiesR50CA243627 · NCI · JOHNS HOPKINS UNIVERSITY · PI Ludmila Danilova · 2019 to 2026
$975kNCI NIH HHS P30 CA006516NCI NIH HHS P30 CA006973NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA101942NCI NIH HHS R01 CA142779NCI NIH HHS R50 CA243627NCI NIH HHS T32 CA193145
Abstract
With a rapidly developing immunotherapeutic landscape for patients with metastatic clear cell renal cell carcinoma, biomarkers of efficacy are highly desirable to guide treatment strategy. Hematoxylin and eosin (H&E)-stained slides are inexpensive and widely available in pathology laboratories, including in resource-poor settings. Here, H&E scoring of tumor-infiltrating immune cells (TIL
Indexed as
Carcinoma, Renal CellBiomarkers, TumorHumansPrognosisBiomarkers, TumorbiomarkerH&EimmunotherapyirPRCnecrosispathologic responsePBRM1PD-1RCCTIL
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.